Question special
Chief Resident

The side effect (SE) profile for dapagliflozin in DAPA trial is very impressive and was not quite different from placebo in the control group when used on top of other GDMT.

Is the drug really as safe as placebo or is this effect due to very close monitoring and appropriate dosage adjustment in the trial pts?

I ask this question because the previous trials with DAPA have demonstrated various SE (most common being urogenital infections but then also euglycemic DKA as well as increased risk of amputations with use of canagliflozin etc)

Is this benign SE profile unique for this member (dapagliflozin) of SGLT2i, or is it due to close monitoring of trial pts? Does this hold true from your experience in clinical practice when you prescribe it to diabetics?